Bril F, Cusi K. Nonalcoholic fatty liver disease: The new complication of type 2 diabetes mellitus. Endocrinol Metab Clin N Am. 2016;45:765–81.

Article  Google Scholar 

Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action. Diabetes Care. 2017;40:419–30.

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56.

Article  CAS  PubMed  Google Scholar 

Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74:989–91.

Article  PubMed  Google Scholar 

Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76–7.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.

Article  PubMed  Google Scholar 

Balta S. Atherosclerosis and non-alcoholic fatty liver disease. Angiology. 2022;73:701–11.

Article  CAS  PubMed  Google Scholar 

Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021;10(3):467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109–17.

Article  PubMed  Google Scholar 

Leey J, Cusi K. Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Aliment Pharmacol Ther. 2018;47:1220–1.

Article  CAS  PubMed  Google Scholar 

Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism. 2021;123: 154868.

Article  CAS  PubMed  Google Scholar 

Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, Hong X, Cheng Y, Wu Q, Zhang X, Feng Z, Wang M. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis. Front Endocrinol (Lausanne). 2022;13: 934225.

Article  PubMed  Google Scholar 

Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incidente cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2023;72:1433–6.

Article  PubMed  Google Scholar 

Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fbrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79–85.

Article  CAS  PubMed  Google Scholar 

Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol. 2020;18:2324-2331.e4.

Article  PubMed  Google Scholar 

Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Liver fbrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol. 2021;36:2960–6.

Article  CAS  PubMed  Google Scholar 

Han E, Lee YH, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Kim SU. Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease. Gut Liver. 2022;16:786–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168–85.

Article  CAS  PubMed  Google Scholar 

Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110:921–93721.

Article  PubMed  Google Scholar 

•Zhang L, She ZG, Li H, Zhang XJ. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond). 2020;134:1775–99. This review summarizes the key molecular events and cellular factors contributing to the metabolic burden induced by NAFLD on atherosclerosis.

Article  CAS  PubMed  Google Scholar 

•Li M, Wang H, Zhang XJ, Cai J, Li H. NAFLD: an emerging causal factor for cardiovascular disease. Physiology (Bethesda). 2023;38(6):0. This review summarizes the evidence from prospective clinical and Mendelian randomization studies that underscore the potential causal relationship between NAFLD and cardiovascular disease.

Bali AD, Rosenzveig A, Frishman WH, Aronow WS. Nonalcoholic fatty liver disease and cardiovascular disease: causation or association. Cardiol Rev. 2023;24:e000537.

Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clin Lipidol. 2012;7:471–81.

Article  CAS  Google Scholar 

Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022;24:533–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behbodikhah J, Ahmed S, Elsayi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites. 2021;11:690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cole J, Zubirán R, Wolska A, Jialal I, Remaley AT. Use of apolipoprotein B in the era of precision medicine: time for a paradigm change? J Clin Med. 2023;12:5737.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matikainen N, Taskinen MR, Stennabb S, Lundbom N, Hakkarainen A, Vaaralahti K, Raivio T. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. Eur J Endocrinol. 2012;166:487–92.

Article  CAS  PubMed  Google Scholar 

Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2022;19:168–79.

Article  CAS  PubMed  Google Scholar 

Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J. 2022;43:1413–5.

Article  PubMed  Google Scholar 

de la Parra Soto LG, Gutiérrez-Uribe JA, Sharma A, Ramírez-Jiménez AK. Is apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies. Nutr Metab Cardiovasc Dis. 2022;32:295–308.

Article  PubMed  Google Scholar 

Deprince A, Hennuyer N, Kooijman S, Pronk ACM, Baugé E, Lienard V, et al. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism. Hepatology. 2023;77:1287–302.

Article  PubMed  Google Scholar 

Hafiane A, Gianopoulos I, Sorci-Thomas MG, Daskalopoulou SS. Current models of apolipoproteina A-I lipidation by adenosine triphosphate binding cassette transporter A1. Curr Opin Lipidol. 2022;33:139–45.

Article  CAS  PubMed  Google Scholar 

Naito C, Hashimoto M, Watanabe K, Shirai R, Takahashi Y, Kojima M, Watanabe R, Sato K, Iso Y, Matsuyama TA, Suzuki H, Ishibashi-Ueda H, Watanabe T. Facilitatory effects of fetuin-A on atherosclerosis. Atherosclerosis. 2016;246:344–51.

Article  CAS  PubMed  Google Scholar 

Gupta RM, Libby P, Barton M. Linking regulation of nitric oxide to endothelin-1: the yin and yang of vascular tone in the atherosclerotic plaque. Atherosclerosis. 2020;292:201–3.

Article  CAS  PubMed  Google Scholar 

Rafnsson A, Matic LP, Lengquist M, Mahdi A, Shemyakin A, Paulsson-Berne G, Hansson GK, Gabrielsen A, Hedin U, Yang J, Pernow J. Endothelin-1 increases expression and activity of arginase 2 via ETB receptors and is co-expressed with arginase 2 in human atherosclerotic plaques. Atherosclerosis. 2020;292:215–23.

Article  CAS  PubMed  Google Scholar 

Loffredo L, Baratta F, Ludovica P, Battaglia S, Carnevale R, Nocella C, Novo M, Pannitteri G, Ceci F, Angelico F, Violi F, Del Ben M. Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis. 2018;28:143–9.

Article  CAS  Google Scholar 

Jiang M, Zhao XM, Jiang ZS, Wang GX, Zhang DW. Protein tyrosine nitration in atherosclerotic endothelial dysfunction. Clin Chim Acta. 2022;529:34–41.

Article  CAS  PubMed  Google Scholar